MedicalSystem Biotechnology Co., Ltd. Class A

MedicalSystem Biotechnology Co., Ltd. Class A

SSZSE:300439
9.33
CNY
-0.12
(-1.27%)
0.27EPS
38.93P/E
3.93BMarket Cap

Total Valuation

CNY

As of September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A carries a market capitalization of 3.93B, placing it among publicly traded companies globally. Its enterprise value stands at 3.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.93B
Enterprise Value3.01B

Share Statistics

As of September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A has 383.84M shares outstanding.

Shares Outstanding383.84M

Valuation Ratios

As of September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 38.93. The price-to-sales ratio is 2.33, and the price-to-book ratio stands at 1.29.

PE Ratio38.93
PS Ratio2.33
PB Ratio1.29
P/TBV Ratio1.34

Enterprise Valuation

As of September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A trades at an EV/EBITDA multiple of 32.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 32.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.01B versus a market cap of 3.93B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.79
EV / EBITDA32.02
EV / EBIT32.02

Financial Position

As of September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A maintains a current ratio of 3.27, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.03, indicating elevated leverage, while an interest coverage ratio of 36.19 demonstrates strong ability to service its debt obligations.

Current Ratio3.27
Quick Ratio1.64
Debt / Equity3.03
Debt / EBITDA0.98
Interest Coverage36.19

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A posted a return on equity (ROE) of 3.35, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.05 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.72, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.34, useful for judging operating efficiency across full business cycles. The company generates approximately 866,722.33 in revenue per employee across its workforce of 1,936.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.15 indicates how many times MedicalSystem Biotechnology Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)3.35
Return on Assets (ROA)2.72
Return on Invested Capital (ROIC)3.05
Return on Capital Employed (ROCE)3.34
Revenue Per Employee866,722.33
Employee Count1,936.00
Inventory Turnover4.15

Taxes

CNY

Over the twelve months ended September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A recorded 228,407.65 in income tax expense. That works out to an effective tax rate of 0.22, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 101.75M, leaving 100.51M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax228,407.65
Effective Tax Rate0.22

Stock Price Statistics

CNY

As of the close on November 17, 2026, MedicalSystem Biotechnology Co., Ltd. Class A's stock has declined approximately 14.48% over the past 52 weeks. The 50-day moving average sits at 9.69, while the 200-day moving average is 9.52.

52-Week Price Change-14.48%
50-Day Moving Average9.69
200-Day Moving Average9.52

Income Statement

CNY

Over the twelve months ended September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A generated 1.68B in revenue and converted that into 100.51M in net income, yielding earnings per share of 0.27. EBITDA reached 93.98M, while operating income came in at 109.26M.

Revenue1.68B
Gross Profit585.27M
Operating Income109.26M
Pretax Income101.75M
Net Income100.51M
EBITDA93.98M
EBIT93.98M
Earnings Per Share (EPS)0.27

Balance Sheet

CNY

As of September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A holds 1.01B in cash and equivalents against 91.88M in total debt, resulting in a net debt position of -327.90M. Total book value stands at 3.04B, with working capital of 1.40B providing operational flexibility.

Cash & Cash Equivalents1.01B
Total Debt91.88M
Net Debt-327.90M
Equity (Book Value)3.04B
Book Value Per Share7.92
Working Capital1.40B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-152.67M

Margins

Over the twelve months ended September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A posted a gross margin of 34.88, reflecting its pricing power and cost economics. The operating margin of 6.51 and net profit margin of 5.99 provide insight into operational efficiency.

Gross Margin34.88
Operating Margin6.51
Pretax Margin6.06
Profit Margin5.99
EBITDA Margin5.60

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A paid dividends of 0.03 per share. The dividend payout ratio of 11.74 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.76, meaning MedicalSystem Biotechnology Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.03
Payout Ratio11.74
Shareholder Yield-0.76

Stock Splits

MedicalSystem Biotechnology Co., Ltd. Class A's most recent stock split took place on September 17, 2015 with a 1:3 split ratio.

Last Split Date9/17/2015
Split Ratio1:3

Scores

As of September 30, 2026, MedicalSystem Biotechnology Co., Ltd. Class A has an Altman Z-Score of 5.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.02